EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access

Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial With Controlled Human Malaria Infection

Lauren P Jatt iD, Kevin M Gillespie, Phuong Van, Stephen L Hoffman, Lisa A Jackson, Sean C Murphy iD, James R Heath iD, James G Kublin iD

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiaf435 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Lauren P Jatt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Hauptthemen laut MEDLINE: Cytokines, Malaria, Malaria Vaccines, Malaria, Falciparum. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases of the National Institutes of Health, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ensuring the safety and efficacy of candidate vaccines is critical. Although mechanisms underpinning protective immune responses to malaria vaccines are frequently investigated, immune responses correlating with moderate and severe adverse events (AEs) are rarely examined. Here, we leverage a malaria vaccine trial with a higher-than-expected AE rate and frequent sampling to investigate cytokine profiles associated with AEs. We found that Interleukin-6 was elevated on days in which individuals experienced moderate and severe AEs. More research on immune responses associated with AEs is warranted in order to identify biomarkers associated with systemic reactogenicity and accelerate vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytokinesMalariaMalaria VaccinesMalaria, FalciparumSporozoitesAdolescentAdultFemaleHumansMaleYoung AdultBiomarkersInterleukin-6Plasmodium falciparum

Stichwörter der Autor:innen

IL-6adverse eventscontrolled human malaria infectioncytokinevaccine

Substanzen

BiomarkersCytokinesInterleukin-6Malaria Vaccines

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington.
  • Sanaria Inc., Rockville, Maryland.
  • Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.
  • Department of Microbiology, University of Washington, Seattle, Washington.

ORCID-Profile: Lauren P Jatt, Sean C Murphy, James R Heath, James G Kublin

Förderung

  • National Institute of Allergy and Infectious Diseases of the National Institutes of Health
  • NIAID NIH HHS

Zitieren

APA

Jatt, L. P., Gillespie, K. M., Van, P., Hoffman, S. L., Jackson, L. A., Murphy, S. C., Heath, J. R., & Kublin, J. G. (2026). Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial With Controlled Human Malaria Infection. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf435

Vancouver

Jatt LP, Gillespie KM, Van P, Hoffman SL, Jackson LA, Murphy SC, et al. Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial With Controlled Human Malaria Infection. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf435

BibTeX
@article{Jatt2026,
  author = {Jatt, Lauren P and Gillespie, Kevin M and Van, Phuong and Hoffman, Stephen L and Jackson, Lisa A and Murphy, Sean C and Heath, James R and Kublin, James G},
  title = {Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial With Controlled Human Malaria Infection},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiaf435}
}
Kostenlos starten →